精彩内容近期,各大跨国药企相继公布2025年Q1财报。根据各家营收成绩,Q1排名前十依次是:强生、罗氏、默沙东、辉瑞、阿斯利康、艾伯维、诺华、礼来、诺和诺德、BMS,赛诺菲以微弱的差距落于名单之外。同时,肿瘤领域一直是跨国药企的“必争之地”,默沙东的K药依旧稳坐头把交椅创收超70亿美元,强生的Darzalex(达雷妥尤单抗)紧随其后;减重领域风头正盛,礼来与诺和诺德的竞争正在走向白热化.........
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.